1
|
Wormsbaecher C, Hindman AR, Avendano A, Cortes-Medina M, Song JW, Burd CJ. Abstract 2687: The estrogenic activities of endocrine disruptors alter the extracellular matrix and tissue stiffness in the mammary gland. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In utero exposure to estrogenic endocrine disrupting compounds (EDCs) increases a woman’s lifetime risk of breast cancer. Similarly, mice exposed in utero to the estrogenic EDC bisphenol A (BPA) have increased susceptibility to mammary gland tumors. It is unclear which BPA-induced alterations predispose the mammary gland to cancer transformation. There is a critical need to understand the mechanisms that drive increased cancer risk in order to assess the impact of BPA and BPA alternatives that retain estrogenic activity. We have utilized in utero BPA exposure as a model system for in utero estrogenic endocrine disruption to study the long-term consequences to the mouse mammary stroma. We found that BPA exposed fibroblasts showed significant transcriptional deregulation, with the extracellular matrix being the most altered cellular component and multiple collagen genes being more highly expressed. The fibroblasts from the BPA exposed mice decreased fluid permeability of the extracellular matrix, indicative of an increased density in the extracellular matrix. Also, in utero BPA exposure increased mammary gland stiffness. Changes to breast density, stiffness, and collagen deposition are all associated with breast cancer risk. Further, we test BPA alternative compounds with varying affinities for the estrogen receptor in our in utero model to assess the phenotypes in the mouse mammary stroma which are associated with breast cancer risk. Additionally, we use a mesenchymal estrogen receptor alpha (ERα) knockout mouse model to dissect the in utero cellular target of EDCs.
Citation Format: Clarissa Wormsbaecher, Andrea R. Hindman, Alex Avendano, Marcos Cortes-Medina, Jonathan W. Song, Craig J. Burd. The estrogenic activities of endocrine disruptors alter the extracellular matrix and tissue stiffness in the mammary gland [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2687.
Collapse
|
2
|
Wormsbaecher C, Hindman AR, Avendano A, Cortes-Medina M, Jones CE, Bushman A, Onua L, Kovalchin CE, Murphy AR, Helber HL, Shapiro A, Voytovitch K, Kuang X, Aguilar-Valenzuela R, Leight JL, Song JW, Burd CJ. In utero estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness. Breast Cancer Res 2020; 22:41. [PMID: 32370801 PMCID: PMC7201668 DOI: 10.1186/s13058-020-01275-w] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 04/02/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND In utero endocrine disruption is linked to increased risk of breast cancer later in life. Despite numerous studies establishing this linkage, the long-term molecular changes that predispose mammary cells to carcinogenic transformation are unknown. Herein, we investigated how endocrine disrupting compounds (EDCs) drive changes within the stroma that can contribute to breast cancer susceptibility. METHODS We utilized bisphenol A (BPA) as a model of estrogenic endocrine disruption to analyze the long-term consequences in the stroma. Deregulated genes were identified by RNA-seq transcriptional profiling of adult primary fibroblasts, isolated from female mice exposed to in utero BPA. Collagen staining, collagen imaging techniques, and permeability assays were used to characterize changes to the extracellular matrix. Finally, gland stiffness tests were performed on exposed and control mammary glands. RESULTS We identified significant transcriptional deregulation of adult fibroblasts exposed to in utero BPA. Deregulated genes were associated with cancer pathways and specifically extracellular matrix composition. Multiple collagen genes were more highly expressed in the BPA-exposed fibroblasts resulting in increased collagen deposition in the adult mammary gland. This transcriptional reprogramming of BPA-exposed fibroblasts generates a less permeable extracellular matrix and a stiffer mammary gland. These phenotypes were only observed in adult 12-week-old, but not 4-week-old, mice. Additionally, diethylstilbestrol, known to increase breast cancer risk in humans, also increases gland stiffness similar to BPA, while bisphenol S does not. CONCLUSIONS As breast stiffness, extracellular matrix density, and collagen deposition have been directly linked to breast cancer risk, these data mechanistically connect EDC exposures to molecular alterations associated with increased disease susceptibility. These alterations develop over time and thus contribute to cancer risk in adulthood.
Collapse
Affiliation(s)
- Clarissa Wormsbaecher
- Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Andrea R Hindman
- Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Alex Avendano
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
- Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA
| | - Marcos Cortes-Medina
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
- Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA
| | - Caitlin E Jones
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
- Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA
| | - Andrew Bushman
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
- Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA
| | - Lotanna Onua
- Department of Chemical and Biomedical Engineering, The Ohio State University, Columbus, OH, USA
| | - Claire E Kovalchin
- Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Alina R Murphy
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Hannah L Helber
- Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Ali Shapiro
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Kyle Voytovitch
- Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Xingyan Kuang
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | | | - Jennifer L Leight
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
- Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA
| | - Jonathan W Song
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
- Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH, USA
| | - Craig J Burd
- Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA.
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
| |
Collapse
|
3
|
Hindman AR, Mo XM, Helber HL, Kovalchin CE, Ravichandran N, Murphy AR, Fagan AM, St. John PM, Burd CJ. Varying Susceptibility of the Female Mammary Gland to In Utero Windows of BPA Exposure. Endocrinology 2017; 158:3435-3447. [PMID: 28938483 PMCID: PMC5659685 DOI: 10.1210/en.2017-00116] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Accepted: 07/31/2017] [Indexed: 11/19/2022]
Abstract
In utero exposure to the endocrine disrupting compound bisphenol A (BPA) is known to disrupt mammary gland development and increase tumor susceptibility in rodents. It is unclear whether different periods of in utero development might be more susceptible to BPA exposure. We exposed pregnant CD-1 mice to BPA at different times during gestation that correspond to specific milestones of in utero mammary gland development. The mammary glands of early-life and adult female mice, exposed in utero to BPA, were morphologically and molecularly (estrogen receptor-α and Ki67) evaluated for developmental abnormalities. We found that BPA treatment occurring before mammary bud invasion into the mesenchyme [embryonic day (E)12.5] incompletely resulted in the measured phenotypes of mammary gland defects. Exposing mice up to the point at which the epithelium extends into the precursor fat pad (E16.5) resulted in a nearly complete BPA phenotype and exposure during epithelial extension (E15.5 to E18.5) resulted in a partial phenotype. Furthermore, the relative differences in phenotypes between exposure windows highlight the substantial correlations between early-life molecular changes (estrogen receptor-α and Ki67) in the stroma and the epithelial elongation defects in mammary development. These data further implicate BPA action in the stroma as a critical mediator of epithelial phenotypes.
Collapse
Affiliation(s)
- Andrea R. Hindman
- Department of Molecular Genetics, The Ohio State University, Columbus, Ohio 43210
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210
| | - Xiaokui Molly Mo
- Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210
| | - Hannah L. Helber
- Department of Molecular Genetics, The Ohio State University, Columbus, Ohio 43210
| | - Claire E. Kovalchin
- Department of Molecular Genetics, The Ohio State University, Columbus, Ohio 43210
| | | | - Alina R. Murphy
- Department of Molecular Genetics, The Ohio State University, Columbus, Ohio 43210
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210
| | - Abigail M. Fagan
- Department of Chemistry, State University of New York New Paltz, New Paltz, New York 12561
| | - Pamela M. St. John
- Department of Chemistry, State University of New York New Paltz, New Paltz, New York 12561
| | - Craig J. Burd
- Department of Molecular Genetics, The Ohio State University, Columbus, Ohio 43210
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210
| |
Collapse
|